Background Single nucleotide polymorphisms (SNPs) are the most common source of genetic variation. Although microvascular pathology is associated with cardiovascular events, genetic phenotypes causing microvascular disease remain largely unknown. This study identifies sex-specific SNPs associated with coronary microvascular dysfunction.
Introduction
Many genomic variants underlie variations causing cardiovascular disease. The large numbers of new loci associated with cardiovascular risk factors, subclinical indexes, and disease end points have provided insights into the biologic pathways that underlie disease [1] . Although conventional risk factors are important, both rare and common genetic variants account for more than 50% of an individual's susceptibility to coronary heart disease (CHD) [2] . Single nucleotide polymorphisms (SNPs) are the most common sources of genetic variations [2] .
The development of CHD depends on an individual's genetic predisposition and accumulation of risk factors that lead to a wide array of molecular and cellular abnormalities within the vessel wall, such as those related to sustenance and regeneration of microvessels [3] . These abnormalities can contribute toward the development of coronary microvascular dysfunction and atherosclerosis [3] .
Coronary microvascular dysfunction, defined as abnormal coronary flow reserve (CFR) in response to adenosine, is associated with an increased annual major adverse cardiovascular event rate, which includes death, nonfatal myocardial infarction, nonfatal stroke, and congestive heart failure [4] . Previous studies on the genetic predictors of cardiovascular disease have primarily focused on macrovascular disease traits and genetic analyses of microvascular disease phenotypes that are unavailable, although both macrovascular and microvascular pathology are associated with cardiovascular disease [5] .
Several studies show sex-specific variations in coronary microcirculation [6] [7] [8] ; however, there is a lack of understanding as to how sex-related pathobiologic and genetic differences influence the development of vascular abnormalities that underlie CHD. Knowledge of such genotypic predictors may enhance our understanding of the molecular mechanisms causing coronary microvascular dysfunction. Thus, the current study was designed to assess the association between SNPs and invasive assessment of coronary microvascular dysfunction in humans and to investigate the sex-specific SNPs related to coronary microvascular dysfunction.
Methods

Study population
This study includes 643 participants (426 women and 217 men) who underwent invasive coronary microcirculatory assessment from 1993 to 2010. The referral for cardiac catheterization and coronary microvascular function testing was made at the discretion of the referring cardiologist and the operating interventionalist. Patients did not have significant fixed coronary artery stenosis, meaning that they had less than 30% obstruction in their coronary arteries. The majority of participants were of European ancestry (93% white + 5.6% unknown and presumed white). The median age was 51 for women (range 20-75) and 46 for men (range 18-78).
Predefined exclusion criteria were unstable angina pectoris, uncontrolled systemic hypertension, valvular heart disease, left ventricular ejection fraction less than 40%, and/or significant endocrine, hepatic, renal, or inflammatory disease. Systemic hypertension was defined as a history of elevated blood pressure requiring longterm therapy. Hypercholesterolemia was defined as either a total cholesterol serum concentration of at least 240 mg/dl or intake of lipid-lowering therapy. The diagnosis of diabetes mellitus was made on the basis of the patient's clinical record.
The study was approved by the Mayo Clinic Institutional Review Board, and informed consent was obtained from every patient. This study complies with the Helsinki Declaration of 1975, as revised in 2008.
Study protocol
As described previously [9] [10] [11] [12] [13] [14] , all patients refrained from taking any vasoactive medication for at least 36 h before catheterization. Patients refrained from consuming any food, drinks, and tobacco for at least 12 h before catheterization. Diagnostic coronary angiography was performed using a 6 or 7 Fr guiding catheter with a standard femoral percutaneous approach. Unfractionated intravenous heparin was administered to achieve an activated clotting time of B250 s. Nonionic contrast material was used for all patients. No nitroglycerin was administered before the diagnostic procedure.
Coronary vascular reactivity responses were studied, as reported previously [9] [10] [11] [12] . In brief, a 0.014-inch Doppler tipped guidewire (FloWire; Volcano Corp., San Diego, California, USA) was introduced into the left anterior descending coronary artery. CFR was assessed by escalating doses of an intracoronary bolus injection of adenosine (36-60 mg) until maximal CFR was obtained. Doppler flow velocity spectra were analyzed on-line to determine averaged peak velocity. CFR was calculated as the ratio of maximal coronary blood flow (CBF) induced by adenosine to basal CBF.
Patients were divided into two groups according to a CFR greater than, less than, or equal to 2.5. These cut-off points were derived from previous reports [9] [10] [11] [12] . Impaired coronary microvascular function was defined as CFR less than 2.5 and favorable coronary microvascular function was defined as CFR more than or equal to 2.5. Furthermore, the patients were subclassified into two groups stratified by sex.
Genomic data and blood collection
DNA was extracted from all samples at the same time, after storing them all at -801C, by the Biospecimens Accessioning and Processing facility. Picogreen analysis was run on all samples to assess quality. The data were genotyped at the Mayo Genotyping Core facility using an Illumina custom GoldenGate panel (Illumina Inc., San Diego, California, USA) [15] . Per 96-well plate, there were 85 unique samples, five duplicate DNA samples, and six quality control samples. A total of 1529 autosomal tag SNPs and seven SNPs on the X chromosome were originally chosen to represent 76 genes with known associations to coronary vasoreactivity, angiogenesis, inflammation, artery calcification, atherosclerosis risk factors, female hormone, blood coagulation system, or prevalence of CHD. Of these, 351 were eliminated from the analysis because of minor allele frequencies less than 5%, Hardy-Weinberg equilibrium P-values less than 0.001, or SNP call rates less than 95% (i.e. missing values for at least 5% of the participants). The majority of SNPs failed because they were monomorphic (had the same value for all participants) or had a very low minor allele frequency (an alternate SNP value was observed in only a few participants). Genetic positions are listed in Build 36 (National Center for Biotechnology and Information, Bethesda, Maryland, USA). Expanded methods are included in the supplementary materials.
Ethical considerations
This study was approved by the Mayo Clinic Institutional Review Board. This study also complies with the principles stated in the Declaration of Helsinki. All patients enrolled in the study signed consent forms after reviewing the protocol for the study, which included the risks, burdens, and benefits of the study. Precautions were taken to maintain the confidentiality of all identifying patient information utilized in this study using secure firewalled, password-secured databases, and special precautions were taken to prevent patients undergoing cardiac catheterization from receiving any unnecessary punctures.
t-test and summarized using mean±SD. Logistic regression was run using the endpoint of CFR less than 2.5 to determine whether genetic differences existed after adjusting for age, sex, and BMI, assuming a log-additive genetic model. Models were also run testing for a sex-SNP interaction. A P-value of less than 0.005 was considered statistically significant (Table 1) . Statistical analysis was carried out using Plink 1.07 (Purcell, Cambridge, Massachusetts, USA) [16] .
Results
Patient characteristics
A total of 643 patients underwent physiologic coronary testing in the cardiac catheterization laboratory [426 women and 217 (34%) men]. Patient characteristics are summarized in Table 1 . The median age was 51 for women (range 20-75) and 46 for men (range 18-78). Women had a significantly lower CFR than men (2.8±0.6 vs. 3.2±0.8, P < 0.001).
Comparisons between the abnormal and the normal CFR group are shown in Table 2 . Age was significantly higher in the abnormal CFR group than in the normal group (53.4±11.0 vs. 48.2±11.2 years, P < 0.001). BMI and the proportion of men were significantly lower in the abnormal CFR group than in the normal CFR group (27.8±5.5 vs. 29.5±6.3, P < 0.001; 2.2 vs. 3.3, P < 0.001, respectively). There were no differences in the prevalence of diabetes, hypertension, dyslipidemia, family history, and smoking between the two groups. On the basis of this analysis, age, sex, and BMI were used as adjustors before investigation of the SNPs. Figure 1 presents the Manhattan plot showing the minus log-transformed P-values for the individual 1529 SNPs against their genomic position. The solid horizontal line marks the threshold for significance (P = 0.005). The top SNPs that are associated with an increased risk of abnormal CFR are shown in Table 3 . This includes one signal within the gene VEGFA (vascular endothelial growth factor A) represented by one SNP [odds ratio (OR) = 1.68, P = 0.004] and one signal within the gene CDKN2B-AS1 (CDKN2B antisense RNA1) represented by five correlated SNPs (top SNP's OR = 1.5, P = 0.003).
Relationship of SNPs with abnormal CFR
Sex-specific differences observed in SNPs related to abnormal CFR
We tested for the differential effects of SNPs in terms of abnormal CFR for men and women by testing for SNPsex interactions (Table 4) 
. Figures 2 and 3 present
Manhattan plots showing minus log-transformed P-values for the individual SNPs against their genomic position in women and men, respectively. The solid horizontal line marks the threshold for significance (P = 0.005). Genes with at least one SNP that had different effects between men and women include MYH15, VEGFA, and NT5E.
Among these four SNPs (Table 4 ) associated with those genes, the OR for the SNPs ranged from 2.27 to 2.85 for men (P-values from 0.0006 to 0.0029) and from 1.06 to 1.25 for women (no P < 0.005). Values are given as n (%) or mean (SD). ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CFR, coronary flow reserve; ERT, estrogen replacement therapy. Overall
P-values (minus log-transformed) of the entire population are shown in a signal intensity (Manhattan) plot relative to their genomic position. Each SNP is plotted with respect to its chromosomal location (x-axis) and its P-value (y-axis on the left). The solid horizontal line indicates the threshold for significance in our study (P = 0.005). The dashed line represents a standard P-value (P = 0.01). SNP, single nucleotide polymorphism. 
Discussion
In this current study, we have indicated novel regions of genetic variation within VEGFA and CDKN2B-AS1 genes that are associated with coronary microvascular dysfunction.
Furthermore, there were sex-specific differences in SNPs associated with microvascular dysfunction. This study may support a role for genetic variation in the heterogeneity of CBF reserve that can lead to myocardial ischemia. 
SNPs related to the increased risk of abnormal CFR
Our study showed that the risk alleles of VEGFA and CDKN2B-AS1 gene SNPs reside at introns that are associated with an increased risk of abnormal CFR.
Coronary morphogenesis constitutes the proliferation and migration of angioblasts, tube formation, and further assembly of the vascular wall [17] . Regulators of this process are multiple growth factors including VEGF. During the early stage in myocardial vascularization, VEGF expression is related closely to the sites of vascular tube formation and microvascular permeability [17] . The role of VEGF and its receptors is not only to generate new vessels but to control the function of the vascular system in its on-going process. Recent evidence indicated the potential effects of polymorphism in VEGFA genes on the development of CHD [3, 17, 18] . The decrease in VEGFA function induced by gene variants is correlated with vascular dysfunction, including microvascular cell damage, impaired microvascular cell survival, decreased antiapoptotic effect of VEGF, and abnormal vascular repair [19] . All of these VEGF functions can lead to the development of coronary atherosclerosis. The current study suggests that polymorphisms in the VEGF gene are candidate contributors toward the pathogenesis of coronary microvascular dysfunction.
Recently, a major genetic susceptibility locus for CHD was identified. This locus is located within 9p21.3, mapping to the large noncoding antisense RNA transcript Chr1  Chr2  Chr3  Chr4  Chr6  Chr7  Chr8  Chr9  Chr10  Chr11  Chr13  Chr14  Chr15  Chr16  Chr17 Chr22 Chr19 X P-values (minus log-transformed) of men adjusting for age are shown in a signal intensity (Manhattan) plot relative to their genomic position. Each SNP is plotted with respect to its chromosomal location (x-axis) and its P-value (y-axis on the left). The solid horizontal line shows the threshold for significance in our study (P = 0.005). The dashed line represents a standard P-value (P = 0.01). SNP, single nucleotide polymorphism.
CDKN2BAS, formerly called ANRIL [20] . ANRIL is expressed in vascular endothelial cells and coronary smooth muscle cells [21] . Genetic variants of CDKNBAS are associated with angiogenesis and atherosclerosis pathogenesis in vascular cells by mediating the response to inflammatory signaling [22] . Modulations of the expression levels of CDKN2BAS may affect vascular cell proliferation and senescence. Its deficiency may cause vascular injury in patients with microvascular dysfunction.
Sex differences of SNPs related to abnormal CFR Cardiovascular structural and functional adaptation to aging and disease differs considerably between women and men [23] . Women with symptomatic ischemic heart disease undergoing coronary angiography have less extensive or obstructive coronary lesions than men [23, 24] . Despite this, women have a poorer prognosis compared with men, suggesting the existence of a female-specific pattern of coronary artery disease (CAD) with a high frequency of coronary microvascular dysfunction [23, 24] .
In the current study, we observed sex-specific differences in SNPs and some duplication in the gene regions of vasculature and MYH15 without overlap of SNPs between women and men. Sex-specific differences in microvascular blood flow and vasodilatory capacity are observed very early in development. In a study on skin microcirculation in newborn preterm (24-28 weeks) infants, female infants had a lower baseline flow than males [25] . This suggests that the mechanism of myocardial ischemia in women may be localized to the microvascular coronary arteries, and that abnormal microvascular function may have prognostic implications [26] .
Polymorphisms in MYH15 are associated with myocardial infarction and an increased risk of CHD [27] . MYH15 encodes myosin heavy polypeptide 15 [27] . Further studies are needed to clarify how MYH15 might be involved in vascular biology or how this polymorphism in the downstream region of MYH15 affects the risk of vascular disease between women and men.
In men, the gene variant of NT5E is associated with abnormal CFR. Mutations in NT5E are associated with arterial calcification [28] . This gene encodes CD73, which converts adenosine monophosphate into adenosine, supporting a role for this metabolic pathway in inhibiting vascular calcification [28, 29] . CD73 deficiency leads to a reduction in extracellular adenosine levels, causing vascular calcification. Double knockout mice for the NT5E gene have reduced but not absent levels of adenosine [30] , indicating NT5E SNPs' role in microvascular dysfunction.
Han et al. [31] described sex differences in atheroma burden and CFR in patients with early coronary atherosclerosis, showing that men have greater atheroma burden and more eccentric atheroma than women and that CFR was significantly lower in women than in men. The gene variant in NT5E may play a role in the vascular calcification and function of adenosine, and its role may depend on sex-specific differences. The effect of NT5E SNP rs6922 on risk is independent of all known risk factors, including dyslipidemia, hypertension, diabetes, obesity, and markers of inflammation; this implies a new biologic pathway that is relevant to CHD in that its effects on adenosine working normally as a vasodilator might possibly be lacking and subsequently lead to earlier development of coronary microvascular dysfunction in patients with this SNP.
The aspects that may account for the differences in outcomes between women and men are related to vascular genetic and biological factors such as a smaller atheroma burden and slower progression in women, lower CFR, more vascular stiffness, differences in remodeling, and functional differences in smooth muscle cells in the wall.
Clinical implications
The vast majority of cardiovascular diseases are polygenic, with both heritable and environmental contributions. Familial segregation of cardiovascular disease suggests that these diseases share a common genetic predisposition that interacts with the environment and may predispose individuals to vascular disorders, which manifest at different time points throughout life. This study suggests that the mechanism of the development of microvascular dysfunction observed in men may be different from that in women and may suggest that treatment options will need to be tailored in specific ways.
Although most SNPs that we identified as significantly associated with abnormal CFR lie within currently presumed noncoding intronic sequences, there are several potential mechanisms that could explain their association. These SNPs may be in linkage disequilibrium with promoter SNPs that have not yet been identified or that were not genotyped in this study. Furthermore, these intronic SNPs may have promoter functions that have not yet been identified, and intronic variants may potentially affect receptor function through alternative splicing mechanisms. SNPs in the 5 0 upstream region could play a significant role in affecting gene transcription, and those in the 3 0 untranslated region can alter mRNA stability and participate in the development of human disease.
Limitations
This study has several limitations. First, this is a crosssectional study and we have not studied follow-up of cardiovascular events in these patients. Second, the sample size is relatively limited and therefore the significance level used (0.005) does not fully account for the multiple testing issues with the SNPs. Given 1185 SNPs and the correlation between the SNPs, the significance level should theoretically be set at 7.1e -5 to retain a type I level of 0.05. However, to detect ORs that are clinically reasonable in the range of 1.5-2, this study would need to be triple the sample size. Therefore, we have chosen a lower significance cut-off, recognizing that there are false-positive results that need to be validated in additional cohorts. Third, we limited the analysis to White patients as we had insufficient number of non-White patients to date to allow for statistical accommodation of gene admixture. Our findings were not definitive and should be viewed as exploratory until further validation studies are carried out in other White populations with microvascular dysfunction. Although we have indicated regions that contain genetic variants associated independently with coronary microvascular dysfunction, there is considerable linkage disequilibrium within these regions and the SNPs identified are only indicators that there may be associations in these regions. We do not have a validation set. Because of the challenge of obtaining such a physiologically quantified group and because the assessment of CFR with adenosine in patients without CAD is performed in very few centers, we do not have a validation set. To our knowledge, we are the only center performing CFR assessment with adenosine as well as collecting blood samples on patients without CAD. Finally, our findings do not identify mechanistic pathways that link identified SNP associations to the development of coronary microvascular dysfunction. Further investigation is required to determine how these SNPs associations identified in this study relate to the development of coronary microvascular dysfunction.
Conclusion
This clinical study suggests that genetic variations within defined regions of VEGFA and CDKN2B-AS1 genes are associated with coronary microvascular dysfunction. Furthermore, there are sex-specific differences in genetic variation in alleles MYH15, VEGFA, and NT5E that are associated with an increased risk of coronary microvascular dysfunction in men. Finally, there was no overlap of SNPs related to microvascular dysfunction when the analysis is run separately for women and men. Our findings may help focus research on novel genes and pathways involving the microvasculature and its role in the pathogenesis and development of CHD, and lead to potential future directed therapy.
